Find your way through NEUVIOR

Website directory

• Home

  See NEUVIOR’s programmes in medicines intelligence, biomedical research, and pharmaceutical materials and energy, including PHARMORIS and glioblastoma research.

• About NEUVIOR

  Discover the meaning and pronunciation of NEUVIOR, our founder, our beginnings and the purpose behind medicines intelligence, biomedical research and regenerative economics.

• Founder

  Read Varun Sharma’s perspective on building NEUVIOR, bringing scientific and creative freedom to medicines technology, research, and industrial innovation.

• Medicines Intelligence

  Discover NEUVIOR’s medicines intelligence work through PHARMORIS: evidence review, implementation and value for pharmacy, primary care, hospitals and health systems.

• PHARMORIS

  Explore PHARMORIS, the Medicines Action Layer being developed by NEUVIOR to connect medicines evidence, professional decisions, implementation and value review.

• How PHARMORIS works

  Follow the PHARMORIS workflow from a medicines opportunity and source-linked evidence to human review, implementation planning, and outcome evaluation.

• PHARMORIS-SCOT

  Explore PHARMORIS-SCOT: Scottish feasibility research into medicines prioritisation, expert-reviewable evidence and the practical case for adoption.

• PHARMORIS-INDIA

  Explore NEUVIOR’s India-facing PHARMORIS development direction: locally defined medicines decisions, buyer value and a focused evaluation approach.

• Biomedical Research

  Explore NEUVIOR’s biomedical research approach, beginning with glioblastoma recurrence, cell-state biology, selective intervention questions and meaningful patient priorities.

• Glioblastoma Recurrence Programme

  Explore NEUVIOR’s glioblastoma recurrence research questions: treatment-surviving cell states, causal regrowth, GPX4-related vulnerability and neural-function preservation.

• Research

  Discover the research questions behind NEUVIOR’s medicines intelligence, biomedical and resource programmes, and the evidence each next step needs.

• Understanding glioblastoma

  Read accessible explanations of glioblastoma, diagnosis, treatment, recurrence, cell states, and the research questions behind NEUVIOR’s programme.

• What is glioblastoma

  Understand glioblastoma through modern diagnosis, brain location and the difference between a scan, a molecular result and the research questions they inform.

• Causes and risk factors

  Understand glioblastoma risk without personal blame: inherited and tumour changes, population evidence and the difference between disease origin and survival.

• Diagnosis IDH and MGMT

  Understand how scans, tissue, IDH and MGMT contribute different information, why test methods matter and how molecular findings should be read in context.

• Treatment and supportive care

  Explore how surgery, radiotherapy, chemotherapy and supportive care fit together, with treatment evidence, historical trial limits and the importance of function.

• Why glioblastoma returns

  Understand why glioblastoma can regrow: infiltrating cells, changing states, supporting populations and the evidence needed to distinguish response from control.

• Cell states and treatment survival

  Explore glioblastoma cell states, quiescence and treatment survival, including why a changing biological programme is different from a fixed tumour identity.

• GPX4 and ferroptosis

  Understand GPX4 and ferroptosis as a research rationale, including state-specific vulnerability, causal evidence, exposure and the need to preserve neural function.

• The brain environment

  Explore how glioblastoma interacts with neurons and surrounding tissue, why experimental context matters and how research can examine function alongside control.

• From research to treatment

  Follow the journey from a glioblastoma mechanism to a development decision, including model evidence, exposure, clinical-trial purposes and meaningful comparisons.

• Resource Economics

  Explore NEUVIOR’s work on pharmaceutical energy, bio-derived materials and resource recovery, connecting scientific performance with the economics of adoption.

• ZYLON

  Explore ZYLON’s completed initial feasibility record and the application-led questions behind bio-derived materials, recovery, characterisation and industrial adoption.

• PHARMORIS-ECO

  Explore PHARMORIS-ECO’s research into predictive energy optimisation for fixed pharmaceutical chilling and freezing, alongside process stability and industrial adoption.

• Build the next stage of NEUVIOR

  Explore NEUVIOR’s medicines-intelligence commercial thesis, evidence priorities and a considered route to requesting investment information.

• Research and development investment

  Explore how a defined study can change a development decision across NEUVIOR medicines intelligence, resource research and biomedical programmes.

• Research collaboration

  Explore focused research collaboration with NEUVIOR across medicines intelligence, glioblastoma biology, industrial resources and meaningful public involvement.

• Build with NEUVIOR

  Find the right way to contribute to NEUVIOR: specialist work, academic research, commercial evaluation or an expression of interest in future roles.

• For health-system medicines leaders

  A starting point for NHS trust and ICB medicines leaders: compare implementation, discharge pathways and operational value before discussing a focused PHARMORIS evaluation.

• For pharmaceutical organisations

  Find the NEUVIOR research direction that fits your next pharmaceutical decision: medicines implementation, manufacturing resources, materials or translational collaboration.

• For pharmacy owners and teams

  Find a practical starting point for an independent pharmacy, small group or pharmacy team: recurring work, service follow-through and a focused medicines-intelligence discussion.

• Insights

  Read NEUVIOR’s thinking on medicines implementation, research methods, glioblastoma biology, and the materials and energy behind pharmaceutical production.

• Press and company news

  Find NEUVIOR company news, programme announcements, approved company information, and a contact route for media enquiries.

• Publications and methods

  Read about NEUVIOR’s research questions and the place of publications, methods, and study outputs across medicines, biology, and industrial research.

• Research updates

  Follow developments in NEUVIOR’s medicines, biomedical, materials, and energy programmes, including the questions and decisions shaping the next stage.

• Contact

  Contact NEUVIOR about PHARMORIS, research collaboration, industrial development, investment, team opportunities, or media enquiries.

• Trust centre

  A practical starting point for evaluating NEUVIOR programmes, evidence, intended use and the next worthwhile conversation.

• Product and programme status

  Understand the current public development stage of PHARMORIS, research, Resource Economics and Constellation, and what a discussion can establish.

• Frequently asked questions

  Answers about NEUVIOR, PHARMORIS, research, Constellation and the practical next step for customers, collaborators or investors.

• Growth worth sustaining.

  NEUVIOR’s recorded 2045 net-zero direction, Evergreen Level 2 preparation and Level 3 ambition, with current-position documents and evidence work.

• Support and milestones

  Read NEUVIOR’s development milestones, founder-recorded 34-day selection story and source-linked Innovate UK and Scottish Enterprise support.

• NEUVIOR Constellation

  Explore NEUVIOR Constellation: a scientific destinations concept connecting research, enterprise and public discovery, with an ambition for eight locations by 2045.

• Campus development model

  Read about campus development model at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Formulation strategy

  Read about formulation strategy at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Analytical development

  Read about analytical development at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Manufacturing readiness

  Read about manufacturing readiness at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Illustrative capability examples

  Read about illustrative capability examples at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Medicines development explained

  Read about medicines development explained at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Intelligent operations

  Read about intelligent operations at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Scientific and technical capabilities

  Read about NEUVIOR’s proposed capability models across formulation, analysis, translational science, laboratory automation, quality, and manufacturing readiness.

• Process & Industrial Chemistry

  Read about process & industrial chemistry at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Bioprocessing & Biological Systems

  Read about bioprocessing & biological systems at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Translational Biology & Human-Relevant Models

  Read about translational biology & human-relevant models at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Surgical Robotics & Human-Machine Intervention

  Read about surgical robotics & human-machine intervention at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Autonomous Laboratories & Closed-Loop Discovery

  Read about autonomous laboratories & closed-loop discovery at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Scientific AI & Model Governance

  Read about scientific ai & model governance at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Digital Twins & Cyber-Physical Operations

  Read about digital twins & cyber-physical operations at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Packaging, Materials & Device Interfaces

  Read about packaging, materials & device interfaces at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Quality Assurance & Regulatory Science

  Read about quality assurance & regulatory science at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Sustainable Chemistry, Waste & Utilities

  Read about sustainable chemistry, waste & utilities at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Laboratory benchmarks

  Read about laboratory benchmarks at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Public discovery and skills

  Read about public discovery and skills at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Campus sustainability

  Read about campus sustainability at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Campus market and users

  Read about campus market and users at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Campus readiness

  Read about campus readiness at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Campus governance

  Read about campus governance at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Campus evidence library

  Read about campus evidence library at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Shape the Constellation concept

  Help shape NEUVIOR Constellation around scientific demand, workable shared services, public discovery and a credible route to development.

• Campus development and investment

  Read the development logic, evidence requirements, prospective users, and funding questions behind NEUVIOR’s proposed science campus programme.

• Discuss the Constellation investment thesis

  Frame a Constellation investment discussion around demand, operating economics, phased capital and the evidence needed before a campus commitment.

• Campus site diligence

  Read about campus site diligence at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Varun Sharma on evidence led campus development

  Read about varun sharma on evidence led campus development at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Varun Sharma visits AMIDS during Constellation exploration

  An August 2026 visit to AMIDS informs NEUVIOR’s exploration of Scotland within the Constellation scientific destinations concept.

• Campus updates

  Read about campus updates at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• What makes a science campus credible?

  Read about what makes a science campus credible? at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Why Glasgow City Region is being evaluated for a proposed medicines campus

  Read about why glasgow city region is being evaluated for a proposed medicines campus at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Why formulation and analytical science should shape medicines infrastructure

  Read about why formulation and analytical science should shape medicines infrastructure at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Designing responsible AI and robotics for future medicines operations

  Read about designing responsible ai and robotics for future medicines operations at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Luxury beauty licensing: who owns the brand, formula, factory and risk?

  Read about luxury beauty licensing: who owns the brand, formula, factory and risk? at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Campus programme status

  Read about campus programme status at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Accessibility

  Choose a practical way to read NEUVIOR, use interactive explanations or request an alternative when a page creates a barrier.

• After Publication

  Read about after publication at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Clinical governance

  Frame a PHARMORIS evaluation around accountable medicines decisions, local governance, escalation and reviewable evidence of the workflow.

• A guided PHARMORIS briefing

  Prepare a guided, non-clinical PHARMORIS briefing around one medicines workflow, a useful comparison and a clear next evaluation decision.

• How to read our evidence

  Understand the difference between a programme ambition, a source-backed result and the evidence needed for a real-world medicines decision.

• Evidence and intended impact

  How NEUVIOR separates reported innovation support, proposed benefits and the evidence needed to demonstrate useful outcomes.

• Origins and connections

  NEUVIOR’s Scottish origin, international conversations and approach to building purposeful research and medicines collaborations.

• Medicines markets

  How NEUVIOR approaches medicines evidence across distinct markets, with practical questions for pharmacy, health system and industrial collaborators.

• Responsible supply. A public record.

  NEUVIOR’s preserved signed voluntary modern-slavery statement for 2026, with a new reader’s guide and an accessible text alternative.

• PHARMORIS assurance

  How NEUVIOR approaches PHARMORIS assurance: intended use, professional responsibility, source quality, information handling and evidence relevant to evaluation.

• Platform responsibilities

  Explore the commercial responsibilities, source permissions, interfaces and handovers a buyer should assess before a PHARMORIS integration evaluation.

• Quality and assurance

  Connect a PHARMORIS claim to its intended use, assessed version, evidence and next decision through a proportionate quality and assurance review.

• Regulatory and assurance context

  Examine intended use, assessment scope and the evidence needed for a potential PHARMORIS evaluation without inferring certification or deployment.

• Responsible AI

  Examine a bounded AI task, the evidence behind its output and the human work needed to verify it before considering a PHARMORIS evaluation.

• Security and data

  Define the permitted data, responsibilities, evidence and recovery questions for a bounded PHARMORIS security assessment without exposing private architecture.

• Principles and governance publications

  NEUVIOR’s company-authored positions on local accountability, prescribing services, third-party data and the conversion of innovation support into useful work.

• Standards/Prescribing Service Accountability

  A NEUVIOR governance principle separating prescribing authority, commissioned service accountability, digital responsibilities, incidents and review.

• Standards/Standardisation And Local Accountability

  A NEUVIOR governance principle for common standards, authorised local adaptation, operating review, exceptions and accountable learning.

• Standards/Third Party Data Responsibility

  A NEUVIOR authored governance principle for third party data roles, access, monitoring, incidents, notifications, continuity, recovery and secure exit.

• Standards/Innovation Conversion Ledger

  A NEUVIOR proposal for reporting how publicly supported innovation progresses to paid testing, repeat procurement, justified stopping and learning.

• A footprint we can explain.

  Read NEUVIOR’s retained April 2026 carbon plan and a new review draft separating its recorded 2045 direction from the inventory still to complete.

• 2045. Build the evidence behind it.

  NEUVIOR’s existing 2045 company-wide net-zero commitment and the inventory, governance and reporting needed to turn direction into measurable progress.

• United States conversations

  A focused programme of US conversations about pharmacy operations, medicines evidence and responsible AI, with practical questions for prospective evaluation collaborators.

• Privacy policy

  Read about privacy policy at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Cookie policy

  Read about cookie policy at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• Website terms

  Read about website terms at NEUVIOR, the evidence behind the work, and the decisions required for its next stage.

• From pilot theatre to financial grip: how NHS CFOs should evaluate AI in medicines optimisation

  A practical framework for NHS finance leaders to test whether medicines AI can create governable value within existing financial rules.

• The NHS has not finished the generic job

  Why generic prescribing rates do not close the NHS medicines productivity question, and where accountable implementation still matters.

• The quarterly medicines leakage report every ICB should want in 2026/27

  A proposed quarterly medicines leakage view for integrated care boards, connecting opportunity, ownership, delivery and evidenced value.

• NHS digital programmes do not fail on dashboards. They fail on deployment

  Why medicines dashboards are not enough, and what NHS digital programmes need to connect a signal with accountable implementation.

• Best-value biological medicines are the clearest near-term medicines productivity play in the NHS

  Why best value biological medicines deserve disciplined NHS attention, with implementation, ownership and measurement kept visible.

• From medicines intelligence to campus development

  Varun Sharma examines how medicines intelligence can inform proposed scientific infrastructure, with Glasgow and Hyderabad remaining at predevelopment stage.

• From hyperfocus to governed execution

  Varun Sharma reflects on neurodivergent systems thinking and the controls that turn founder insight into accountable execution.

• After NICE: making medicines access operational

  A practical founder reflection on the accountable operating work required after a NICE recommendation.

• When three medicines numbers can all be right

  Varun Sharma explains how to reconcile medicines figures without hiding different definitions, assumptions or decision contexts.

• The 30p rule: how discipline builds trust

  A founder reflection on the corner shop lesson that connects unit economics, record quality and commercial trust.

• A trade deal is not a patient pathway

  Varun Sharma reflects on the proposed five gate implementation ledger for India UK pharmaceutical trade.

• What feasibility research must prove

  A founder reflection on the evidence gates that turn early research activity into a defensible next decision.

• What feasibility support should actually buy

  Varun Sharma explains how early feasibility support should be governed, measured and separated from adoption or outcome claims.

• From invention to adoption: the work between

  Varun Sharma reflects on the operating work between an invention and responsible adoption without reproducing a paywalled letter.

• AI and Accountability: When Does a Suggestion Become a Decision?

  Listen to Varun Sharma on AI Ethics Now, a University of Warwick IATL podcast, discussing human responsibility, false confidence and accountable AI decisions.

• Approval is not access: Pilots' real test is implementation

  Read NEUVIOR's summary of Varun Sharma's pharmaphorum analysis on medicines access, local pathway readiness, implementation and transparent governance.

• Five questions to test whether an AI stack is truly under your control

  Read NEUVIOR's summary of Varun Sharma's TechRadar Pro framework for AI provenance, infrastructure control, legal authority and safe switching or exit.

• India’s pharma quality reset will be won after the inspector leaves

  Read NEUVIOR’s summary of Varun Sharma’s ET Pharma commentary on durable remediation, visible accountability and human judgement in pharmaceutical quality.

• Medicines intelligence development portfolio

  Explore PHARMORIS and NEUVIOR’s medicines-intelligence development directions in evidence review, implementation planning, supply resilience and value assurance.

• Evidence review

  A medicines-intelligence development direction focused on traceable sources, explicit uncertainty and efficient professional review.

• Implementation planning

  Explore NEUVIOR’s development direction for connecting medicines decisions with ownership, dependencies, sequencing and review.

• Medicines supply resilience

  A research direction exploring how medicines teams could compare availability decisions across time, locations and operational constraints.

• Medicines value assurance

  Explore how NEUVIOR’s medicines-intelligence development connects an original value case with implementation, resource use and subsequent review.

• How our research progresses

  Understand how NEUVIOR shapes research questions, meaningful comparisons, appropriate methods, permissions and evidence-led development decisions.

• Survivor-cell biology

  A proposed research collaboration to distinguish treatment survival from causal contribution to glioma regrowth, with model-specific tracking and measurable comparisons.

• Target engagement and selectivity

  Explore a proposed GPX4-related mechanism study connecting engagement, exposure, lipid oxidation, selectivity and recovery before a development decision.

• Neural-function preservation

  A proposed neuroscience collaboration examining activity, model relevance and recovery alongside malignant-cell effects, without inferring clinical neuroprotection.

• From mechanism to development

  A proposed translational research collaboration connecting exposure, model choice, formulation questions and reproducibility with a staged feasibility decision.

• Sources and media credits

  Data sources, research references, creators and context for the photography, films, publication marks and interactive experiences used on the NEUVIOR website.

• Community pharmacy programme

  Explore NEUVIOR’s community pharmacy development direction: useful medicines handovers, service follow-through and evidence that makes sense for independent owners and their teams.

• Pharmacy groups and networks

  Explore NEUVIOR’s development direction for pharmacy groups, national chains and online providers: comparable evidence, accountable implementation and branch-level value.

• PHARMORIS evidence cases

  Explore the evidence-development questions behind PHARMORIS: review effort, implementation, human factors and medicines continuity.

• Medicines intelligence for primary care

  Explore NEUVIOR’s medicines-intelligence direction for general practice, PCNs and clinical pharmacy: useful evidence, implementation and a focused PHARMORIS evaluation.

• Medicines intelligence for hospitals and health systems

  A pharmacy-led approach to medicines evidence, implementation and value for NHS providers, ICBs and health systems. Explore a focused PHARMORIS evaluation with NEUVIOR.

• Medicines intelligence in the United States

  Explore NEUVIOR’s US evaluation interest in pharmacy-led evidence and implementation, with distinct roles for health systems, community pharmacies, health plans and public programmes.

• Medicines intelligence for pharma and industry

  Explore NEUVIOR’s medicines-intelligence direction for pharmaceutical businesses, suppliers and SMEs: evidence, adoption barriers, implementation and a focused PHARMORIS evaluation.

• Explore medicines data

  Explore England’s 2025/26 community dispensing by BNF chapter using official NHSBSA data, with exact prescription-item counts, ingredient costs and source definitions.

• When quality becomes a capital decision

  A proposed manufacturing-quality evaluation linking operational uncertainty, investment options and measurable decision evidence.

• Which supply exception deserves attention first?

  Explore a proposed wholesale exception-review evaluation that compares effort, escalation and operational consequences.

• Before a shortage becomes everybody’s problem

  A proposed readiness review for marketing authorisation holders connecting supply evidence, reporting ownership and action.

• A forecast needs a reason to be believed

  Explore demand uncertainty, stock movement and the evidence needed before a pharmaceutical supply decision changes.

• The lowest price is only one part of the tender

  A proposed medicines tender evaluation comparing price, capacity, delivery conditions and supply resilience.

• When the temperature moves, the evidence must keep up

  A proposed cold-chain evidence-preparation review for accountable medicines quality teams.

• A recall message is only useful when the action is clear

  Explore a proposed recall-readiness exercise focused on product identity, communication, ownership and evidence of completion.

• Give the unanswered question a useful shape

  A proposed medical-affairs evidence-gap review connecting stakeholder questions, available evidence and study decisions.

• Access is a decision. Adoption is a journey.

  Explore a proposed industry review of local medicines implementation, capacity assumptions and evidence for market-access decisions.

• Can the available data answer the question?

  A proposed feasibility review for industry real-world evidence studies, with a clear question, comparator and data-fit decision.

• Public medicines data. A sharper commercial question.

  Explore how public medicines datasets could support bounded business decisions without overstating market size, prices or access.

• Governed AI begins with a decision about its role

  A proposed AI-use evaluation for medicines organisations defining context, responsibility, evidence and limits before adoption.

• A convincing summary is not enough

  A proposed evaluation of AI-assisted medicines evidence preparation using source accuracy, omissions and reviewer effort.

• From a changed document to a clear next question

  A proposed regulatory-intelligence triage review connecting official changes, product relevance and accountable assessment.

• Before a product leaves the portfolio

  A proposed discontinuation decision review connecting commercial constraints, supply implications, reporting and alternatives.

• Traceability has to work when something does not match

  A proposed US medicines traceability exception-review study for manufacturers, distributors and dispensers.

• The handoff is part of the manufacturing decision

  A proposed contract-manufacturing decision review connecting responsibilities, assumptions and implementation evidence.

• Supply is back. What should change next time?

  A proposed post-shortage review distinguishing supply recovery, residual workload and lessons for accountable improvement.

• US independent pharmacy | See the work behind the margin

  A proposed PHARMORIS evaluation for US independent pharmacy owners comparing operational friction, acquisition records and reimbursement uncertainty.

• US retail pharmacy groups | Scale the decision, preserve the differences

  A proposed medicines-intelligence study for US retail pharmacy groups comparing service readiness, local capacity and sustained operational value.

• US health-system pharmacy | Make the next operational choice defensible

  Explore a bounded PHARMORIS study for US health-system pharmacy leaders evaluating a medicines workflow with operational and financial comparators.

• US specialty pharmacy | Understand the journey before calling it access

  A proposed PHARMORIS evaluation of specialty pharmacy referral and administrative handovers, with explicit measures, comparators and data limits.

• US mail-order pharmacy | Look beyond the parcel leaving the building

  A proposed operational evaluation for US mail-order pharmacy teams covering fulfilment exceptions, handovers and the evidence needed for a useful change.

• US health plans | Make the medicines case explicit

  Explore a proposed PHARMORIS evidence-preparation study for US health plans, separating benefit design, operational effort and accountable decision-making.

• US PBM relationships | Ask a sharper contract question

  A proposed medicines-intelligence review for buyers examining PBM-related evidence and contract questions without inferring net prices from public benchmarks.

• US accountable care | Connect a medicines question to the right incentive

  A proposed PHARMORIS evaluation for accountable care organisations, focused on a specific medicines-related workflow and appropriately bounded evidence.

• US Medicaid programmes | Read the state, the programme and the data

  A proposed Medicaid medicines-data review separating state utilisation, reimbursement benchmarks and the local authority needed for evaluation.

• Medicare Part D | Keep the benefit year in the picture

  A proposed PHARMORIS review of Medicare Part D evidence and operational questions, with dated sources and clear limits on plan-level inference.

• 340B | Make the boundary visible before making the business case

  A proposed decision-preparation study for authorised 340B stakeholders, keeping eligibility, operational evidence and financial assumptions distinct.

• US formulary review | A clearer argument deserves a clearer challenge

  A proposed PHARMORIS evidence-preparation study for US formulary and medicines committees, with traceability, comparator and implementation checks.

• India hospital medicines | Compare the service, not just the purchase price

  A proposed medicines-intelligence discussion for Indian hospital sponsors comparing procurement, service delivery and local payment constraints.

• India retail pharmacy | A sharper view of stock, price and working capital

  A proposed medicines-intelligence evaluation for Indian pharmacy businesses, separating local records, official price references and practical operating decisions.

• Australia community pharmacy | Readiness, delivery and the work between

  A proposed PHARMORIS evaluation for Australian community pharmacy services, grounded in local delivery and careful interpretation of PBS data.

• Australia hospital pharmacy | See the implementation behind the option

  A proposed operational evidence study for Australian hospital pharmacy leaders, connecting implementation demands with accountable review and local data.

• Singapore medicines evaluation | Evidence, implementation and local value

  A proposed medicines-intelligence discussion for Singapore institutions and industry sponsors, separating subsidy evidence, local implementation and evaluation authority.

• Across borders | Know what travels and what must be rebuilt

  Explore a proposed PHARMORIS evidence-portability study that tests which medicines decision methods transfer across settings and which require local redesign.

• Independent pharmacy | Make the next service earn its place

  A practical decision framework for independent owners comparing service demand, capacity, costs and cash before expanding.

• Pharmacist time | Find the work that breaks concentration

  Explore a bounded assessment of interruptions, handovers and repeated administration that protects professional attention.

• Small pharmacy groups | Compare branches fairly

  A practical approach to branch comparisons that accounts for local demand, staffing and service mix before choosing improvements.

• Large pharmacy networks | Make rollout a sequence of decisions

  A staged framework for pharmacy networks evaluating whether an operational change deserves wider investment.

• Supermarket pharmacies | Turn access into a coherent service

  Explore the operational questions between supermarket footfall, pharmacy enquiries, clinical capacity and completed services.

• Online pharmacies | Design for continuity beyond the order

  Explore a professional evaluation of remote pharmacy handovers, failed contacts, delivery exceptions and continuity.

• Pharmacy First | Find the friction in the referral journey

  A focused operational evaluation of Pharmacy First referrals, capacity, completion and onward handovers.

• Discharge medicines | Follow the referral to a meaningful next step

  Explore a pharmacy-facing assessment of discharge referral receipt, action, completion and cross-sector handovers.

• New Medicine Service | Make follow-up workable

  A practical evaluation of NMS follow-up scheduling, contact effort and continuity without promising clinical outcomes.

• Blood pressure services | Plan capacity through the whole pathway

  Explore clinic checks, ambulatory monitoring capacity and handovers as a coherent pharmacy operational question.

• Pharmacy claims | Know where completed work becomes payment

  A bounded reconciliation framework separating service delivery, claims, acceptance and cash for pharmacy owners.

• Medicines availability | Understand the work around a shortage

  Evaluate the operational effort, communication and unresolved demand around medicines supply issues without automating clinical substitutions.

• Hub and spoke | Test the whole operating case

  An evidence-led comparison of hub-and-spoke options, transition costs, exceptions and usable branch capacity.

• Consultation space | Make capacity useful, not just full

  Compare competing uses of pharmacy consultation rooms through demand, professional cover, access and economic contribution.

• Pharmacy workforce | Build readiness around the service

  Explore capability, cover and implementation dependencies before introducing a new pharmacy service or workflow.

• Inclusive pharmacy access | Understand who cannot use the journey

  Evaluate communication needs, booking barriers and service access without treating digital uptake as the only success measure.

• Repeat prescriptions | Find the avoidable return journey

  Explore prescription-status uncertainty, repeated contacts and handover friction around repeat medicines.

• Pharmacy pilots | Design a result someone can invest in

  A practical framework for a pharmacy evaluation with a decision owner, comparator, meaningful outcomes and explicit stop criteria.

• Evidence review quality

  Explore a proposed medicines evidence study comparing source fidelity, review quality and total checking effort, with a clear decision for research partners.

• Implementation research

  Investigate why agreed medicines changes stall, where delivery work accumulates and which implementation conditions a pharmacy or health-system partner could test.

• Reproducible medicines analysis

  Explore reproducible medicines analysis that connects source data, calculation and interpretation, giving research partners a result they can check and update.

• Academic and commercial translation

  Connect an academic finding with a credible user, comparator and next experiment, while keeping research rights and commercial translation questions clear.

• Research design for smaller businesses

  Frame a focused research question for a medicines SME, compare realistic alternatives and identify the smallest experiment that could change its next decision.

• AI and professional judgement

  Examine how professionals check, challenge and use AI outputs in medicines work, with proposed studies of appropriate reliance, review quality and total effort.

• Cell states and treatment resistance

  Explore model-specific questions about changing cell states and treatment resistance, with credible controls, responsible methods and a bounded research proposal.

• Formulation feasibility research

  Explore early formulation questions around stability, measurement and reproducibility, with a defined comparator and evidence needed for a development decision.

• Industrial measurement research

  Examine whether an industrial measurement can support a medicines process decision, including reference methods, uncertainty, operating conditions and full effort.

• Public involvement in research

  Shape medicines research with the people affected, through proposed public-involvement partnerships that offer clear influence, support and feedback on decisions.

• PHARMORIS buyer demand

  Examine PHARMORIS demand through a recurring medicines task, an accountable buyer and a realistic purchasing route, with evidence needed before further investment.

• Recurring workflow value

  Explore when repeated medicines work could support continuing PHARMORIS value, comparing subscriptions, periodic services and the full cost of staying useful.

• From pilot to contract

  Examine how a focused PHARMORIS evaluation could inform a buying decision, with a credible comparator, assurance planning and clear conditions for continuation.

• Evidence as a commercial asset

  Explore how credible, reusable PHARMORIS evidence could improve buyer understanding, with clear claim boundaries, independent challenge and appropriate rights.

• Constellation demand before build

  Examine Constellation demand before development, comparing occupier needs, existing provision and a smaller first programme while keeping location options open.

• Shared infrastructure economics

  Explore a shared research capability through real usage, specialist support and operating costs, comparing new provision with access to existing infrastructure.

• Public discovery value

  Examine Constellation public discovery through audience needs, useful engagement and sustainable operation, beginning with a pilot before a permanent museum.

• Eight destinations, earned in stages

  Explore the ambition for eight Constellation destinations by 2045 through staged evidence, local purpose and a tested reason to build a connected research network.

• Solvent recovery that earns its return

  A solvent leaving a process can be an expense, a useful material or a difficult mixture.

• A better solvent must improve the whole process

  Changing a solvent can change far more than the label on a drum.

• Cleaning is a process decision too

  The end of a production batch is the start of another resource-intensive sequence.

• Give each water stream a justified next use

  A pharmaceutical site can contain streams with very different qualities and destinations.

• Choose a water system around its duty

  A pharmaceutical water investment should begin with the required quality and demand pattern, then examine how different systems deliver that duty.

• Find the use for the heat before buying the exchanger

  Waste heat has value when a real demand can use it at the right temperature and time.

• Electrify the duty that can carry the change

  Replacing a heat source is a production decision as well as an energy decision.

• Dry only as far as the product requires

  A drying step can hold valuable equipment while the team waits for confidence in the product.

• Choose continuous processing for a real operating advantage

  A continuous process deserves attention when it solves a defined production problem.

• Follow the catalyst beyond the reaction

  A catalyst may look efficient in the reaction scheme while leaving a difficult separation, contamination question or supply exposure.

• What is worth recovering from the mother liquor?

  After crystallisation, value can remain in a stream that is costly to handle.

• Make purification earn its material demand

  Purification can turn a promising chemistry into an impractical manufacturing process.

• Change the pack without losing the medicine

  Packaging can offer a visible materials story, but its first job is to protect and deliver the medicine appropriately.

• Single-use or reusable needs a fair boundary

  The choice between disposable and reusable processing equipment cannot be settled by counting plastic alone.

• Ask suppliers for evidence that can change a decision

  A supplier's environmental statement is useful when it relates to the material, location and process being purchased.

• Keep a useful stream from becoming a difficult mixture

  Once process streams are mixed, information and recovery options can disappear with them.

• Find the capacity before committing the capital

  A production expansion can appear to require more equipment when the constraint is waiting, changeover, yield loss or an unreliable upstream step.

• Measure the uncertainty that could change the investment

  A resource dashboard can be visually convincing while telling a manufacturer little about what to do next.

• Make the review count. Protect the time around it.

  A clinical pharmacist's diary can be full while the work around a structured medication review remains fragmented.

• The repeat request should not become repeated work.

  A repeat prescription request can pass through several hands before the person receives a clear answer.

• A monitoring task needs an owner, not another reminder.

  A task can look complete in one organisation while remaining unresolved in another.

• A referral sent is not the same as a service delivered.

  The NHS Discharge Medicines Service connects hospital discharge information with community pharmacy support.

• Make the discrepancy visible before it becomes another handoff.

  A medicines list can travel quickly while uncertainty about a change travels with it.

• The referral should arrive with a way forward.

  A referral can be appropriate in principle and still be difficult to complete in practice.

• See the whole outpatient pharmacy choice.

  Hospital outpatient pharmacy choices connect patient experience, clinical responsibility, operational capacity and commercial terms.

• Give the committee a brief it can interrogate.

  A formulary committee needs evidence it can question, not another confident summary that hides the difficult parts.

• A formulary decision is the start of the work.

  A committee can approve a medicines position while implementation still depends on protocols, communications, ordering, training and responsibilities across organisations.

• The lowest price is not the whole supply decision.

  A medicines procurement decision has consequences beyond the quoted price.

• The value of a biosimilar depends on the pathway around it.

  A biological medicines opportunity can require coordination across specialist teams, pharmacy, procurement, administration services and patient communication.

• Give high-cost medicines decisions a clearer local case.

  High-cost medicines bring clinical need, commissioning responsibility and operational delivery into the same conversation.

• Homecare value is experienced between deliveries.

  A homecare medicines service connects prescribing, pharmacy, logistics, nursing support where required and communication with the person receiving treatment.

• Make stewardship review easier to prepare, not easier to bypass.

  An antimicrobial stewardship team needs information that supports careful review under real service pressures.

• Build the review around the resident, not the paperwork.

  Medicines review in a care home brings together the resident, care staff, general practice, pharmacy and sometimes specialist services.

• Choose the improvement the system can actually deliver.

  An integrated care board may face several worthwhile medicines initiatives and limited capacity to deliver them.

• An agreement needs accepted responsibilities to work.

  Shared care depends on more than a document carrying the right title.

• A pilot should leave you with a decision.

  A technology pilot can consume months and still leave a team unsure whether to continue.

• A useful conversation starts with the right information

  Request a NEUVIOR company briefing or discuss an NDA through a clear, considered information process.

• Ideas with a route to responsible use

  Review NEUVIOR’s verified UK word marks, copyright approach, research rights and route to a licensing discussion.

• Team NEUVIOR

  Discover how NEUVIOR brings relevant expertise around medicines questions, with clear ownership, independent challenge and a founder-led direction.

• Careers and expressions of interest

  Introduce your interests and experience to NEUVIOR. Read the distinction between future-role enquiries, specialist commissions and any formally advertised vacancies.

• The resource question behind the next investment

  A manufacturing improvement becomes commercially interesting when someone can decide what to do with it.

• Build the service before the skyline

  A remarkable science campus should be more than a remarkable image.

• The AI pilot should earn the next decision

  An impressive demonstration can start a conversation.

• NEUVIOR Data Analysis

  Inspect source-derived medicines comparisons, public research questions and a transparent catalogue of data, reporting periods, methods and access.